Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...
(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life patients.) ...
More than 500,000 Medicare enrollees signed up for the $50 GLP-1 Bridge in two months what it means for eligibility, costs, and coverage after 2027. New Public Charge Rule Takes Effect Friday, Letting ...
(StatePoint) Like many bladder cancer survivors, Karen S. often reflects on her personal experience with the disease, and the support she received throughout her healthcare journey. Karen was ...
Hosted on MSN
Photocure ASA’s AI-Enhanced Blue Light Cystoscopy: A New Era in Bladder Cancer Detection
Photocure ASA ((PHCUF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Effects of perioperative chemotherapy on prognosis in muscle invasive bladder cancer treated with radical cystectomy. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers ...
OSLO, Norway, Nov. 7, 2022 /PRNewswire/ -- Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services (CMS) has released final payment rates in connection ...
OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results